Recruiting

Observational Study

Sponsor:

Royal Victoria Hospital, Canada

Code:

NCT03113045

Conditions

Cesarean Section Complications

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Interventions

seated time

Study Details

Brief summary:

The study will determine the 90% effective seated time after intrathecal injection of hyperbaric bupivacaine to avoid hypotension in patients undergoing cesarean delivery.

Conditions

Cesarean Section Complications

Study ID

NCT03113045

Start date

Jan 31, 2017

Status verified date

Apr, 2017

Completion date

Jan 31, 2020

Anticipated

Primary completion date

Jan 31, 2019

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with singleton pregnancies scheduled for elective cesarean delivery

Exclusion Criteria:

  • BMI>35
  • Unable to communicate in study language
  • ASA greater than 2
  • Hypertensive disease of pregnancy

Study Design

Enrollment

60 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Seated Time

Pts will be seated for the allocated time depending on the previous patients hypotensive response

Interventions

seated time

Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.

Primary outcome measure

  • Hypotension [ Time Frame: 30 minutes ]

Central Contacts and Locations

Central contacts

Locations

Mcgill University Health Center

Recruiting

Montreal, Quebec, Canada, H2T 1V5

Contacts

More Information

Sponsor

Royal Victoria Hospital, Canada

Last update posted

Apr 13, 2017

Last verified

Apr, 2017

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Royal Victoria Hospital, Canada on 2017-04-13.